LncRNA NORAD as a Novel Predictor of Lymph Node Metastasis and Prognosis in Solid Tumors: A Systematic Review and Meta-Analysis

Tao, Ye; Ye, Zhangqun

doi:10.1177/1533033820963586

Cited by 10 publications

(5 citation statements)

References 41 publications

(51 reference statements)

Supporting

Mentioning

Contrasting

Order By: Relevance

“…The prognostic value of NORAD in human diseases was reported in previous investigations. A meta-analysis reviewed the association between NORAD and clinical outcomes of various cancer patients, and found that high NORAD levels related to a positive lymph node metastasis status and unfavorable survival of patients, which concluded NORAD a valuable prognostic biomarker of human cancers [26]. Downregulation of NORAD in neuroblastoma was demonstrated to predict patients' poor prognosis and advanced tumor stage [27].…”

Section: Discussionmentioning

confidence: 99%

Upregulated lncRNA NORAD can diagnose acute cerebral ischemic stroke patients and predict poor prognosis

Li¹,

Li²,

Xu³

et al. 2023

View full text Add to dashboard Cite

Introduction: Acute cerebral ischemic stroke (AIS) dramatically influences patients' quality of life. lncRNA NORAD (NORAD) has been studied in cerebrovascular diseases, which are potential risk factors for AIS. The specific significance of NORAD is unclear. This study aimed to assess the role of NORAD in AIS, and to provide therapeutic value for its' treatment. Material and methods: A total of 103 AIS patients and 95 healthy individuals (control) were enrolled into this study. Expression level of NORAD in the plasma of all participants was analyzed by PCR. Diagnostic potential of NORAD in AIS was evaluated by ROC analysis, while Kaplan-Meier and Cox regression analyses were conducted to assess its' prognostic value in AIS.Results: A significantly increased level of NORAD was observed in AIS patients compared with healthy individuals. The upregulation of NORAD could dramatically discriminate AIS patients from healthy individuals with high sensitivity (81.60%) and specificity (88.40%). NORAD was positively correlated with patients' high-sensitivity C-reactive protein (hs CRP, r = 0.796), matrix metalloproteinase-9 (MMP9, r = 0.757), and NIHSS scores (r = 0.840), and negatively related to pc-ASPECTS scores (r = -0.607). Moreover, NORAD upregulation was associated with patients' unfavorable prognosis and served as an independent prognostic biomarker, together with NIHSS and pc-ASPECTS scores of AIS patients. Conclusions: NORAD was upregulated in AIS, which can discriminate AIS patients, and was closely correlated with severe development and poor prognosis of patients.

show abstract

Section: Discussionmentioning

confidence: 99%

Upregulated lncRNA NORAD can diagnose acute cerebral ischemic stroke patients and predict poor prognosis

Li¹,

Li²,

Xu³

et al. 2023

View full text Add to dashboard Cite

show abstract

“…LncRNAs such as MALAT1, XIST and NORAD have been proven to be biomarkers for human tumor prognosis [47][48][49]. Also, some studies have shown that HULC expression is dysregulated in digestive system tumors [37,39,50].…”

Section: Discussionmentioning

confidence: 99%

LncRNA HULC as a potential predictor of prognosis and clinicopathological features in patients with digestive system tumors: a meta-analysis

Wang

et al. 2022

Aging

View full text Add to dashboard Cite

Objective: This meta-analysis aimed to evaluate the correlation between lncRNA HULC, prognosis and clinicopathological characteristics in patients with digestive system tumors. Methods: The relevant literatures were collected through PubMed, Web of Science and Embase up to February 2021. Hazard ratios (HRs) and 95% confidence intervals (CIs) were calculated to assess the prognostic value of HULC in patients with digestive system tumors. The clinicopathological characteristics of HULC in patients were estimated by odds ratios (ORs). Results: A total of 14 studies involving 1312 patients were included. The up-regulated expression level of HULC was associated with poorer overall survival (OS) in patients with digestive system tumors (HR = 1.83, 95% CI: 1.05-3.19, P = 0.033). Subgroup analysis showed that cancer type (pancreatic cancer or gastric cancer), residence region (China, Japan or Korea), and specimen (serum) significantly associated between HULC and OS. In addition, high HULC expression significantly increased the risk of high TNM stage (OR = 2.51, 95%CI: 1.36-4.62, P < 0.05), poor differentiation (OR = 1.38, 95%CI: 1.02-1.87, P < 0.05) and lymphatic node metastasis (LNM, OR = 4.93, 95% CI: 3.47-6.99, P < 0.05). Conclusions: High expression level of HULC is related to OS, TNM stage, differentiation and LNM. Therefore, HULC can be used as a new potential predictor for prognosis and clinicopathological features of patients with digestive system tumors.

show abstract

“…Additionally, in surgical practice, they could help in predicting lymph node burden and, therefore, avoid extensive axillary surgery in patients eligible for genomic tests [ 151 ], as it has been done recently with epigenetic signatures [ 152 ]. They could also work as biomarkers to predict objective response rates (ORR) to specific therapies in the neoadjuvant setting so tumor downstaging could be more precisely inferred [ 153 ].…”

Section: The Current Use Of Lncrnas As Clinical Biomarkers In Clinica...mentioning

confidence: 99%

The Clinical Utility of lncRNAs and Their Application as Molecular Biomarkers in Breast Cancer

Arriaga-Canon

Contreras-Espinosa

Aguilar-Villanueva

et al. 2023

IJMS

View full text Add to dashboard Cite

Given their tumor-specific and stage-specific gene expression, long non-coding RNAs (lncRNAs) have demonstrated to be potential molecular biomarkers for diagnosis, prognosis, and treatment response. Particularly, the lncRNAs DSCAM-AS1 and GATA3-AS1 serve as examples of this because of their high subtype-specific expression profile in luminal B-like breast cancer. This makes them candidates to use as molecular biomarkers in clinical practice. However, lncRNA studies in breast cancer are limited in sample size and are restricted to the determination of their biological function, which represents an obstacle for its inclusion as molecular biomarkers of clinical utility. Nevertheless, due to their expression specificity among diseases, such as cancer, and their stability in body fluids, lncRNAs are promising molecular biomarkers that could improve the reliability, sensitivity, and specificity of molecular techniques used in clinical diagnosis. The development of lncRNA-based diagnostics and lncRNA-based therapeutics will be useful in routine medical practice to improve patient clinical management and quality of life.

show abstract

LncRNA NORAD as a Novel Predictor of Lymph Node Metastasis and Prognosis in Solid Tumors: A Systematic Review and Meta-Analysis

Cited by 10 publications

References 41 publications

Upregulated lncRNA NORAD can diagnose acute cerebral ischemic stroke patients and predict poor prognosis

Upregulated lncRNA NORAD can diagnose acute cerebral ischemic stroke patients and predict poor prognosis

LncRNA HULC as a potential predictor of prognosis and clinicopathological features in patients with digestive system tumors: a meta-analysis

The Clinical Utility of lncRNAs and Their Application as Molecular Biomarkers in Breast Cancer

Contact Info

Product

Resources

About